Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader in RNA editing-based gene therapy, today announced that it has been awarded a research grant from The Michael J. Fox...
-
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to...
-
NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease.
-
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline.
-
Avance Clinical to Showcase Asia and China Growth Strategy at BIO Asia–Taiwan 2026
-
호주 아들레이드, July 10, 2026 (GLOBE NEWSWIRE) -- 호주에 본사를 둔 글로벌 임상시험수탁기관(CRO)인 아반스 클리니컬(Avance Clinical)은 7월 15일부터 19일까지 대만 타이베이 난강전시센터(Taipei Nangang Exhibition Center, TaiNEX)에서 열리는 'BIO Asia–Taiwan...
-
Avance Clinical to Showcase Asia and China Growth Strategy at BIO Asia–Taiwan 2026
-
Vect-Horus announces a research evaluation and exclusive license option agreement with Servier.
-
Vect-Horus annonce la conclusion d'un accord portant sur une collaboration de recherche et une option de licence exclusive avec Servier.
-
NeOnc (NASDAQ: NTHI) is entering one of the most significant periods after securing its second IND from the UAE